AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.

AIM ImmunoTech (AIM) reported positive preliminary data from the Phase 1b/2 study evaluating the combination of Ampligen and ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure ...

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible ...

If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...

AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...

Positive results from the NIAGARA Phase III trial showed that UK pharma major AstraZeneca’s (LSE: AZN) Imfinzi (durvalumab) ...